Pemason Pharma Sponsors Drug Information Publication - EMDEX 2018-2019 Edition

Publication of drug information is a costly operation, made more challenging in a harsh economic and resource-limited setting like the sub-Saharan Africa. To sustain its yearly updates and digitize the print editions, EMDEX needed a lifeline in form of sponsorship. Pemason, Nigeria’s leading pharmaceutical firm, promptly said yes to the initiative. The outcome is the onset of a unique partnership that can potentially change the face of healthcare in the region.

Lagos, Nigeria., November 03, 2017 --  EMDEX Limited is pleased to announce the Corporate Sponsor for EMDEX 2018-2019 Edition – PEMASON PHARMACEUTICALS LIMITED. The company has an extensive portfolio of medicines covering every major indication area such as Micropirin, Pemametre and Betaren.

Under this new funding arrangement, Pemason Pharma is providing the much-needed funds to help with EMDEX Drug Information updates and the ongoing development of the digital editions. In return, Pemason will benefit from increased visibility of their brands under special promotional arrangement on all EMDEX platforms namely the Print, Online & Mobile.

What does this mean for the healthcare sector?

 “A lot. It is a win-win situation for all parties. Access to quality drug information for healthcare professionals will translate to better therapeutic decisions and positive drug therapy outcomes for the patient”, said Chris C. Obi, Founder of EMDEX. “By committing more funds to EMDEX work, Pemason Pharma is demonstrating their leadership in both quality medicines and patient care. And our expectation is that other companies will see this as an opportunity to make a difference”

EMDEX 2018 will be focusing on Drug Safety with extended coverage of Parameters for Monitoring & Patient Education. Interaction Checker is another ongoing project that will benefit from this funding agreement.

“The strength of Pemason Pharmaceuticals Ltd lies in the quality of our products and the horizontal management structure that allows for free flow of information as well as input by every staff”, said Pharm. Patrick O. Osele, CEO of Pemason, in a statement released by the company. “Our goal is to make the patient the center-point of healthcare delivery system while making a name with quality”

EMDEX (Essential Medicines Index) is a reference source of drug and therapeutic information used by healthcare professionals in Nigeria and the sub-region, published since 1991. Based on both the WHO Model Formulary and Nigeria’s Essential Drugs List, EMDEX is unique to Nigeria as it also details mainly the pharmaceuticals and allied products approved for use in the country.

EMDEX (Essential Medicines Index) is a reference source of drug and therapeutic information used by healthcare professionals in Nigeria and the sub-region, published since 1991.

Contact:
Chris C. Obi
EMDEX
No. 25, Osolo Way
Ajao Estate, Lagos State, Nigeria
+1-416-526-4245
editor@emdexonline.com
https://www.emdexonline.com

This release was published on openPR.